Abraxis buys Shimoda, subsidiary

Abraxis BioScience has completed acquisition of South Africa's Shimoda Biotech and its subsidiary, Platco Technologies. Abraxis bought the companies for $15 million up-front, plus potential additional payments upon the achievement of specified milestones. Shimoda is combining off-patent molecules with its drug delivery platform, in order to achieve faster onset and improved bioavailability characteristics of that platform. Platco Technologies focuses on the development of novel platinum-based anti-cancer drugs. Shimoda has one product on the market--Dyloject, an injectable painkiller for the treatment of post-surgical pain.

- here's the release

Related Articles:
Abraxis forges cancer licensing deal with Scripps. Report
Abraxis cleaves company into two new outfits. Report
AstraZeneca, Abraxis ink $200M licensing pact. Report
Abraxis seeks FDA approval. Report